NEXGEL (NXGL) IAccess Alpha–Buyside Best Ideas Winter Virtual Conference 2024 summary

Strategic growth initiatives

• Focused on three growth verticals: own medical devices, custom/white label partnerships, and branded products, with a shift to branded products accelerated by the pandemic.

• Expanded manufacturing and packaging capacity through a joint venture, mitigating risk and supporting large customer onboarding.

• Leveraged unique hydrogel technology for diverse applications, emphasizing biocompatibility and customization.

Medical device innovation and pipeline

• Developed a fast-acting diclofenac patch and an adjunct apremilast patch for stubborn lesions, both showing promising early results.

• Advanced a surgical drape that reduces skin tears, targeting licensing opportunities with major industry players.

• Exploring new adhesive applications, such as cataract surgery drapes, with a focus on elderly patient needs.

Consumer health and beauty expansion

• Achieved rapid revenue growth, reaching an $8–9 million annual run rate through organic growth and acquisitions.

• Acquired Kenkoderm (psoriasis care) and Silly George (beauty brand), significantly increasing sales and digital reach.

• Leveraged a large, active email list and social media following to drive consumer engagement and product launches.